 |
 |
Route of Administration |
| |
- Transdermal |
| - Parenteral |
| - Oral |
|
|
Special Formulations |
| |
- Microspheres |
| - Cyclodextrins |
|
|
Physico-Chemical Properties of the Active Pharmaceutical Ingredient |
|
Limited aqueous Solubility |
| |
- Nanoparticles |
- Solubilization Enhancement by e.g.
- Micellar Solubilization |
|
|
Phase of your Development Project |
|
Preclinical Supplies |
|
Clinical Supplies |
|
Toxicology |
|
Safety Pharmacology |
|
Mutagenicity |
|
Carcinogenicity |
|
Adapted to Species and Individual Animal |
|
Process Development |
|
Use of PAT (Process Analytical Technology) Concept of the FDA |
